Regeneron Pharmaceuticals, Inc. Price Chart
Regeneron Pharmaceuticals, Inc. RGO.F Financial and Trading Overview
| Regeneron Pharmaceuticals, Inc. stock price | 952.8 EUR |
| Previous Close | 707.5 EUR |
| Open | 713 EUR |
| Bid | 713 EUR x 2800 |
| Ask | 718 EUR x 2800 |
| Day's Range | 713 - 713 EUR |
| 52 Week Range | 528.3 - 780.7 EUR |
| Volume | 10 EUR |
| Avg. Volume | 8 EUR |
| Market Cap | 77.41B EUR |
| Beta (5Y Monthly) | 0.231338 |
| PE Ratio (TTM) | 10.668701 |
| EPS (TTM) | 31.54 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 686.88 EUR |
RGO.F Valuation Measures
| Enterprise Value | 69.36B EUR |
| Trailing P/E | 10.668701 |
| Forward P/E | 16.14949 |
| PEG Ratio (5 yr expected) | 2.8 |
| Price/Sales (ttm) | 6.2576203 |
| Price/Book (mrq) | 3.2501276 |
| Enterprise Value/Revenue | 5.607 |
| Enterprise Value/EBITDA | 13.663 |
Trading Information
Regeneron Pharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 0.231338 |
| 52-Week Change | 29.81% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 780.7 EUR |
| 52 Week Low | 528.3 EUR |
| 50-Day Moving Average | 705.18 EUR |
| 200-Day Moving Average | 707.01 EUR |
RGO.F Share Statistics
| Avg. Volume (3 month) | 8 EUR |
| Avg. Daily Volume (10-Days) | 6 EUR |
| Shares Outstanding | 108.03M |
| Float | 102.52M |
| Short Ratio | N/A |
| % Held by Insiders | 2.54% |
| % Held by Institutions | 89.64% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 33.81% |
| Operating Margin (ttm) | 38.07% |
| Gross Margin | 55.83% |
| EBITDA Margin | 41.04% |
Management Effectiveness
| Return on Assets (ttm) | 10.43% |
| Return on Equity (ttm) | 19.27% |
Income Statement
| Revenue (ttm) | 12.37B EUR |
| Revenue Per Share (ttm) | 115.42 EUR |
| Quarterly Revenue Growth (yoy) | 6.60% |
| Gross Profit (ttm) | 7.02B EUR |
| EBITDA | 5.08B EUR |
| Net Income Avi to Common (ttm) | 4.18B EUR |
| Diluted EPS (ttm) | 66.831 |
| Quarterly Earnings Growth (yoy) | -16.00000000000000000000000000000000% |
Balance Sheet
| Total Cash (mrq) | 8.96B EUR |
| Total Cash Per Share (mrq) | 83.65 EUR |
| Total Debt (mrq) | 2.7B EUR |
| Total Debt/Equity (mrq) | 11.5 EUR |
| Current Ratio (mrq) | 5.454 |
| Book Value Per Share (mrq) | 219.376 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 4.28B EUR |
| Levered Free Cash Flow (ttm) | 1.71B EUR |
Profile of Regeneron Pharmaceuticals, Inc.
| Country | Germany |
| State | NY |
| City | Tarrytown |
| Address | 777 Old Saw Mill River Road |
| ZIP | 10591-6707 |
| Phone | 914 847 7000 |
| Website | https://www.regeneron.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 12099 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Q&A For Regeneron Pharmaceuticals, Inc. Stock
What is a current RGO.F stock price?
Regeneron Pharmaceuticals, Inc. RGO.F stock price today per share is 952.8 EUR.
How to purchase Regeneron Pharmaceuticals, Inc. stock?
You can buy RGO.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Regeneron Pharmaceuticals, Inc.?
The stock symbol or ticker of Regeneron Pharmaceuticals, Inc. is RGO.F.
How many shares does Regeneron Pharmaceuticals, Inc. have in circulation?
The max supply of Regeneron Pharmaceuticals, Inc. shares is 111.63M.
What is Regeneron Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Regeneron Pharmaceuticals, Inc. PE Ratio is 30.20925700 now.
What was Regeneron Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Regeneron Pharmaceuticals, Inc. EPS is 31.54 EUR over the trailing 12 months.